Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada

31 July 2019

Helsinn Investment Fund Announces First Exit

15 July 2019

Apertura del bando per le borse di studio messe a disposizione dalla Fondazione IBSA

1 July 2019

Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors

26 June 2019

Farmaci generici, il Consiglio Federale attendista sulle nuove disposizioni UE

19 June 2019

Giorgio Calderari, Presidente di Farma Industria Ticino, nominato membro del Consiglio SUPSI

18 June 2019

Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

12 June 2019

Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology

7 June 2019

Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019 – The NEPA IV formulation was evaluated for safety in the AC setting.

4 June 2019

Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania

4 June 2019